Jirát Jan, Zvoníček Vít, Ridvan Luděk, Šoóš Miroslav
Department of Chemical Engineering, University of Chemistry and Technology, Technicka 3, Prague 6,Dejvice 166 28, Czech Republic.
Zentiva, k.s., U kabelovny 130, Prague 10 10237, Czech Republic.
Org Process Res Dev. 2025 Mar 19;29(4):1067-1075. doi: 10.1021/acs.oprd.4c00480. eCollection 2025 Apr 18.
A cocrystallization process of the active pharmaceutical ingredient apremilast with benzoic acid is explored in this work. The aim of the study is to adjust operating conditions during the crystallization to purposefully tune the dissolution properties of the final product. Understanding the cocrystallization is key to obtaining a consistent, high-quality product, as well as tuning other properties such as powder flowability or dissolution properties. It was discovered early in development that the studied cocrystallization process does not follow the common rules of crystallization. Better crystals were obtained at faster cooling rates and worse crystals at slower cooling rates. Interestingly, this can be explained by crystal collisions and a two-phase growth of the crystals. Standard operating conditions were further tested, resulting in different shapes and sizes of the product. Different types of produced crystals were tested in a dissolution apparatus and provided significantly modified dissolution profiles.
本研究探索了活性药物成分阿普斯特与苯甲酸的共结晶过程。该研究的目的是在结晶过程中调整操作条件,以有目的地调节最终产品的溶解性能。了解共结晶过程是获得一致、高质量产品以及调节其他性能(如粉末流动性或溶解性能)的关键。在研发早期就发现,所研究的共结晶过程并不遵循常见的结晶规则。冷却速度较快时可获得更好的晶体,而冷却速度较慢时晶体质量较差。有趣的是,这可以通过晶体碰撞和晶体的两相生长来解释。进一步测试了标准操作条件,得到了不同形状和尺寸的产品。在溶出度仪中对不同类型的生成晶体进行了测试,结果显示溶出曲线有显著变化。